2020 Press Releases

Home»2020 Press Releases
26 05, 2020

Eiger to Present at Jefferies Virtual Healthcare Conference 2020

2020-05-26T21:20:28+00:00

Eiger to Present at Jefferies Virtual Healthcare Conference 2020 PALO ALTO, Calif. – May 26, 2020 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies Virtual Healthcare Conference on June 4, [...]

Eiger to Present at Jefferies Virtual Healthcare Conference 20202020-05-26T21:20:28+00:00
19 05, 2020

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies

2020-05-19T21:14:10+00:00

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies PALO ALTO, Calif. May 19, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug [...]

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies2020-05-19T21:14:10+00:00
7 05, 2020

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

2020-05-07T20:42:20+00:00

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update PALO ALTO, Calif. May 7, 2020 — Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update. “We achieved key milestones [...]

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update2020-05-07T20:42:20+00:00
30 04, 2020

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda

2020-04-30T13:57:03+00:00

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda Six International, Investigator Sponsored Studies Initiating and Enrolling PALO ALTO, Calif. April 30, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients have been dosed in [...]

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda2020-04-30T13:57:03+00:00
27 04, 2020

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies

2020-04-27T13:57:56+00:00

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies Accelerated Assessment of MAA Previously Granted by EMA in March PALO ALTO, Calif. April 27, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that [...]

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies2020-04-27T13:57:56+00:00
3 04, 2020

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic

2020-04-03T11:04:09+00:00

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating   PALO ALTO, Calif. April 1, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare [...]

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic2020-04-03T11:04:09+00:00
23 03, 2020

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

2020-03-23T17:54:46+00:00

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies Progeria MAA Submitted to EMA and Granted Accelerated Assessment PALO ALTO,  Calif. March 23, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, [...]

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies2020-03-23T17:54:46+00:00
13 03, 2020

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

2020-03-13T15:27:43+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA Progeria NDA Submission Complete by End of March 2020 Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif., March 13, 2020 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update2020-03-13T15:27:43+00:00
7 01, 2020

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

2020-01-07T14:48:46+00:00

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer Launch Preparation Underway for Lonafarnib in Progeria Market Development Activities Advancing for HDV Program PALO ALTO, Calif., January 7, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies [...]

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer2020-01-07T14:48:46+00:00
6 01, 2020

Eiger Updates on 2019 Progress and 2020 Milestones Expected

2020-01-06T14:59:42+00:00

Eiger Updates on 2019 Progress and 2020 Milestones Expected Progeria Rolling NDA Planned for Completion in 1Q 2020 HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 Commercial Focus on Progeria Launch Preparation and HDV Market Building Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif., [...]

Eiger Updates on 2019 Progress and 2020 Milestones Expected2020-01-06T14:59:42+00:00